Kairos discovery develops KDX-350, an oral anti-cancer drug candidate for which it reports established preclinical proofs of concept. The company is advancing preclinical programs and is fundraising to prepare the project for clinical transition. Leadership and scientific roles include co-founders Alexandre Arnaud (engineer), Alexandre Bancet (CEO), David Neves (CTO) and researcher Léna Marlhoux (PhD student in collaboration with the Centre de recherche en cancérologie de Lyon). The firm launched a hybrid fundraising campaign on Capital Cell to raise €850,000, combining retail investors, a regional fund and a life‑sciences family office, with roughly 80 investors participating by 11 August 2026 and a €1,000 minimum ticket. Kairos discovery's stated plan is to secure a pharmaceutical partner in 2027 and enter clinical phases in 2028, contingent on producing the necessary supporting data and additional financing.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2026